Abstract：
There is an increasing demand for effective treatments for depression, particularly for individuals grappling with treatment-resistant depression. Over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. However, preliminary findings from phase 2 studies have been inconclusive, prompting critical examination of issues such as maintaining blinding and the role of adjunctive psychotherapy. The maintenance of double-blinding and the role of adjunctive psychotherapy introduce biases that complicate the attainment of conclusive results in clinical research. Examining historical data reveals a recurrent pattern linked to the use of psychoactive substances, which starts with an excess of optimism and ends with general addictive behaviors and a heightened risk of serious public health problems. Considering these findings, a cautious and measured approach is imperative, given that the efficacy and safety of psilocybin treatment have yet to be unequivocally established. The potential for excessive optimism among researchers is a notable concern, as unwarranted enthusiasm may inadvertently facilitate the widespread adoption of this treatment without sufficient empirical support. In navigating the complexities of depression treatment, it is necessary to strike a balance between innovation and prudence to ensure evidence-based advancement of therapeutic approaches.
摘要：
对有效治疗抑郁症的需求越来越大，特别是对于患有难治性抑郁症的个体。近年来,越来越多的兴趣集中在探索psilocybin作为抑郁症的潜在治疗方法的安全性和有效性上.然而,第二阶段研究的初步结果尚无定论，促使对诸如维持致盲和辅助心理治疗的作用等问题进行严格的检查。双盲的维持和辅助心理治疗的作用引入了偏见，使临床研究中的结论性结果复杂化。检查历史数据揭示了与使用精神活性物质有关的反复出现的模式，首先是过度乐观，最后是一般的成瘾行为和严重公共卫生问题的风险增加。考虑到这些发现,谨慎和谨慎的方法是必要的，鉴于psilocybin治疗的有效性和安全性尚未明确确定。研究人员过度乐观的可能性是一个值得注意的问题，因为毫无根据的热情可能会在没有足够经验支持的情况下无意中促进这种治疗的广泛采用。在驾驭抑郁症治疗的复杂性时，有必要在创新和审慎之间取得平衡，以确保基于证据的治疗方法的进步。
